Get the Stockscreener App
4.90
0.62%
0.03
Terns Pharmaceuticals Inc stock is traded at $4.90, with a volume of 717.88K.
It is up +0.62% in the last 24 hours and up +19.51% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$4.87
Open:
$4.82
24h Volume:
717.88K
Relative Volume:
0.72
Market Cap:
$354.59M
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-3.7121
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+13.43%
1M Performance:
+19.51%
6M Performance:
-2.20%
1Y Performance:
-41.25%
1-Day Range:
$4.66
$4.96
1-Week Range:
$3.95
$4.97
52-Week Range:
$1.865
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
4.90 | 354.59M | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Terns Pharmaceuticals’ SWOT analysis: promising pipeline faces competitive CML, obesity markets - Investing.com
SG Americas Securities LLC Purchases 380,489 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Analysts Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) PT at $15.63 - Defense World
Insider Buying: Andrew Gengos Acquires 15,000 Shares of Terns Pharmaceuticals Inc (TERN) - GuruFocus
Terns Pharmaceuticals Approves Directors and Accounting Firm - TipRanks
3 Penny Stocks Wall Street Sees With 243% Upside - 24/7 Wall St.
Squarepoint Ops LLC Has $73,000 Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday - Benzinga
Transcript : Terns Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - marketscreener.com
Two Sigma Investments LP Sells 49,567 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Bank of America Corp DE Purchases 138,661 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
ProShare Advisors LLC Acquires 8,784 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals to Participate in Upcoming June Investor C - GuruFocus
Terns Pharmaceuticals Secures Double Speaking Slots at Major Healthcare Conferences: What to Expect - Stock Titan
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences - GlobeNewswire
D. E. Shaw & Co. Inc. Increases Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Millennium Management LLC Has $8.92 Million Stock Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Nigeria
Nuveen Asset Management LLC Buys 617,009 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
Northern Trust Corp Has $3.28 Million Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Deutsche Bank AG Has $2.21 Million Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
BNP Paribas Financial Markets Acquires New Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Cubist Systematic Strategies LLC Decreases Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Sold by The Manufacturers Life Insurance Company - Defense World
BMO Capital Markets Issues Pessimistic Forecast for Terns Pharmaceuticals (NASDAQ:TERN) Stock Price - Defense World
Terns Pharmaceuticals Selected for Oral Presentation at - GlobeNewswire
Terns Pharmaceuticals Selected for Oral Presentation at European - GuruFocus
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 - The Manila Times
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association ... - Bluefield Daily Telegraph
Breakthrough: New Leukemia Drug TERN-701 Outperforms Standard Treatment in Multiple Resistance Cases - Stock Titan
Terns Pharma (TERN) Price Target Lowered by BMO Capital | TERN S - GuruFocus
Pfizer (PFE): Patent Developments Affect Terns Pharmaceuticals | PFE Stock News - GuruFocus
Pfizer (PFE): Patent Developments Affect Terns Pharmaceuticals | - GuruFocus
Terns Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Dimensional Fund Advisors LP Raises Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Hsbc Holdings PLC Grows Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Terns (TERN) Advances Clinical Programs with Promising Developme - GuruFocus
BRIEF-Terns Pharmaceuticals Q1 Net Income USD -23.908 Million - TradingView
Wells Fargo & Company MN Has $227,000 Stock Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
MetLife Investment Management LLC Acquires 9,500 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
JPMorgan Chase & Co. Reduces Stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Terns Pharmaceuticals Reports Inducement Grants to New Employees - GuruFocus
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) | TERN Stock News - GuruFocus
Biotech Firm Terns Awards Massive 325,000 Share Options Package to New Key Hires - Stock Titan
What is Terns Pharmaceuticals Inc (TERN) Stock Return on Shareholders’ Capital? - Sete News
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Terns Pharmaceuticals Inc Stock (TERN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gengos Andrew | Chief Financial Officer |
Jun 27 '25 |
Buy |
3.93 |
10,000 |
39,283 |
25,000 |
| Burroughs Amy L. | Chief Executive Officer |
Jun 25 '25 |
Buy |
3.87 |
23,314 |
90,230 |
47,083 |
| Gengos Andrew | Chief Financial Officer |
Jun 13 '25 |
Buy |
3.73 |
10,000 |
37,350 |
10,000 |
| Gengos Andrew | Chief Financial Officer |
Jun 16 '25 |
Buy |
3.95 |
5,000 |
19,732 |
15,000 |
| Kuriakose Emil | Chief Medical Officer |
Apr 01 '25 |
Sale |
2.49 |
952 |
2,366 |
53,317 |
| Jung Melita Sun | Chief Business Officer |
Nov 30 '24 |
Buy |
5.11 |
2,250 |
11,498 |
2,250 |
| Burroughs Amy L. | Chief Executive Officer |
Nov 30 '24 |
Buy |
5.11 |
510 |
2,606 |
19,609 |
| Kuriakose Emil | Chief Medical Officer |
Jan 02 '25 |
Sale |
5.71 |
4,481 |
25,607 |
54,269 |
| Vignola Mark J. | Chief Financial Officer |
Jan 06 '25 |
Sale |
5.80 |
9,059 |
52,500 |
74,752 |
| Vignola Mark J. | Chief Financial Officer |
Jan 02 '25 |
Sale |
5.72 |
8,129 |
46,524 |
83,811 |
2.10%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):